相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma
Jessica E. Sagers et al.
SCIENTIFIC REPORTS (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
Alina Malyutina et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Current treatment options for meningioma
Caroline Apra et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2018)
Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2
Diana S. Osorio et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma
Steven P. Angus et al.
NEURO-ONCOLOGY (2018)
Current treatment options for meningioma
Caroline Apra et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2018)
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Claudia Capparelli et al.
CANCER RESEARCH (2018)
A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition
Sang-Oh Yoon et al.
MOLECULAR CELL (2017)
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2017)
Pharmacological targeting of apelin impairs glioblastoma growth
Elizabeth Harford-Wright et al.
BRAIN (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Apelin/APJ system and cancer
Yanjie Yang et al.
CLINICA CHIMICA ACTA (2016)
ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas
Claudia Capparelli et al.
CANCER RESEARCH (2015)
Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma
Claudia Capparelli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms
Martino Ruggieri et al.
SEMINARS IN PEDIATRIC NEUROLOGY (2015)
Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
Yan Luo et al.
ONCOTARGET (2015)
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas
Roberta L. Beauchamp et al.
ONCOTARGET (2015)
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Aline Appert-Collin et al.
FRONTIERS IN PHARMACOLOGY (2015)
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma
Marco Giovannini et al.
NEURO-ONCOLOGY (2014)
Insulin Receptor Signaling in Normal and Insulin-Resistant States
Jeremie Boucher et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2
Feng Yin et al.
CELL (2013)
Sinl phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
Pengda Liu et al.
NATURE CELL BIOLOGY (2013)
RSeQC: quality control of RNA-seq experiments
Liguo Wang et al.
BIOINFORMATICS (2012)
RNA-SeQC: RNA-seq metrics for quality control and process optimization
David S. DeLuca et al.
BIOINFORMATICS (2012)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2012)
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
Jaishri O. Blakeley et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2011)
Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
Timothy R. Wilson et al.
CANCER CELL (2011)
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
Yonghao Yu et al.
SCIENCE (2011)
The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
Peggy P. Hsu et al.
SCIENCE (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Birgit Schoeberl et al.
CANCER RESEARCH (2010)
Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
Wei Li et al.
CELL (2010)
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma
Sylwia Ammoun et al.
NEURO-ONCOLOGY (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]
D. Gareth R. Evans
GENETICS IN MEDICINE (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
Miguel A. Lopez-Lago et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas
D. Lallemand et al.
ONCOGENE (2009)
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
Birgit Schoeberl et al.
SCIENCE SIGNALING (2009)
Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex
Andrea I. McClatchey et al.
TRENDS IN CELL BIOLOGY (2009)
Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type
Chunling Yi et al.
CANCER RESEARCH (2008)
Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection
Kenneth Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Modeling NF2 with human arachnoidal and meningioma cell culture systems:: NF2 silencing reflects the benign character of tumor growth
Marianne F. James et al.
NEUROBIOLOGY OF DISEASE (2008)
ErbB and Nrg: Potential molecular targets for vestibular schwannoma pharmacotherapy
Joni K. Doherty et al.
OTOLOGY & NEUROTOLOGY (2008)
Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis
MS Stonecypher et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis
F Hamaratoglu et al.
NATURE CELL BIOLOGY (2006)
Epidemiology of intracranial meningioma
EB Claus et al.
NEUROSURGERY (2005)
Establishment of a benign meningioma cell line by hTERT-mediated immortalization
S Püttmann et al.
LABORATORY INVESTIGATION (2005)
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
OJ Shah et al.
CURRENT BIOLOGY (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2
T Wiederhold et al.
ONCOGENE (2004)
The WHO classification of tumors of the nervous system
P Kleihues et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling
RJ Shaw et al.
DEVELOPMENTAL CELL (2001)
分享论文
